European Pharmaceutical Review

AUGUST 21, 2023

Q2 2023 biopharma market capitalisation results Eli Lilly “Eli Lilly witnessed the largest market capitalisation growth of 36.1 Lilly completes biopharma acquisitions GlobalData highlighted that Eli Lilly reported its synthetic peptide Mounjaro had $980 million in global sales in Q2. trillion in the Q1 of 2023 to $3.56

Biopharma 79

Biopharma Marketing Sales Medicine 79

Clarivate

JANUARY 8, 2024

Clarivate data indicates a 90% probability that datopotamab deruxtecan will win marketing authorization in the United States, and projects 2029 sales of $2.7 billion in 2029 for CASGEVY alone. FDA accelerated approval in August, Clarivate projects the drug will see $850 million in sales by 2029. billion in 2029 revenues.

Marketing 59

Marketing Patients Healthcare Healthcare 59

Pharmaceutical Technology

APRIL 4, 2023

The Boston, Massachusetts-based Scorpion expects to submit an investigational new drug (IND) application for STX-721 to the US Food and Drug Administration (FDA) in mid-2023, with an IND application for STX-241 expected in H1 2024. billion in 2029. The biopharma aims to start the study as soon as the IND is cleared by the FDA.

Food and Drug Administration 52

Food and Drug Administration Biopharma FDA Pharmaceutical 52